Interim results of the pangaea and PEARL studies, comparing treatment satisfaction and pharmaco-economic data of fingolimod (gilenya®) and first-line therapies in multiple sclerosis patients in Germany

Category Primary study
JournalNeurology
Year 2013
This article has no abstract
Epistemonikos ID: 5c5a4374b7b7f316f7fb42bbd9cb5b31f51bfc0c
First added on: Feb 05, 2025